Department of Medicine

HemHub Seminar Series

Master
Content

Held virtually via zoom: Noon - 1 p.m. (CST)

Zoom Link 
Meeting ID:  387 923 767
Passcode:  831342

Series Schedule
Date Speaker Title/Presentation
Aug. 23, 2021 Lucy A. Godley, M.D., Ph.D.
Hospira Foundation Professor of Medicine and Human Genetics
University of Chicago Medicine
Germline predisposition for myelodysplasia and acute myelogenous leukemia
View Presentation
(BCM login required)
Sept. 20, 2021

Ann Mullally, M.D.
Dana-Farber/Brigham and Women's Cancer Center
Harvard Medical School

Towards Rationally Designed Approaches to Treat Pre-clinical and Overt MPN
View Presentation
(BCM login required)
Oct. 4, 2021

Ola Landgren, M.D., Ph.D.
UHealth, Sylvester Comprehensive Cancer Center
University of Miami Health System

Advances in therapy of relapsed/refractory myeloma
View Presentation
(BCM login required)
Oct. 18, 2021

Justin Lathia, Ph.D.
Cleveland Clinic, Learner Research Institute

Cancer stem cell-immune system interactions drive disease progression
View Presentation
(BCM login required)

Nov. 1, 2021

Robert Kridel, M.D., M.P.H., Ph.D.
University of Toronto

Off the shelf CAR T Cells in B Cell Malignancies
View Presentation
(BCM login required)
Nov. 15, 2021

Charlotte Graham, Ph.D.
Kings College Hospital

Off the shelf CAR T Cells in B Cell Malignancies
View Presentation
(BCM login required)
Nov. 29, 2021

Enrico Derenzini, M.D., Ph.D.
IEO European Institute of Oncology

Exploring the DNA damage response as a therapeutic target in DLBCL?
View Presentation
(BCM login required)
Dec. 13, 2021

Navdeep S. Chandel, Ph.D.
Feinberg School of Medicine, Northwestern University

Unraveling Cancer cell Metabolism
View Presentation
(BCM login required)
Dec. 27, 2021 Michael R. Bishop, M.D.
University of Chicago
Emerging Cellular and Targeted Therapy Options for the Management of Large B-Cell Lymphoma
View Presentation
(BCM login required)
Jan. 10, 2022

Eirini Papapetrou, M.D., Ph.D.
Icahn School of Medicine at Mount Sinai

Identifying novel AML targets
View Presentation
(BCM login required)
Jan. 24, 2022

Philippe Moreau, M.D.
Hematology Department
University Hospital of Nantes, France

Myeloma International Working Group recommendations for treatment of relapsed and refractory disease
View Presentation
(BCM login required)

Feb. 7, 2022

Siddhartha Jaiswal, M.D., Ph.D.
Stanford University

Clonal Hematopoiesis in Human Aging and Disease
View Presentation
(BCM login required)
Feb. 21, 2022

Matteo della Porta, M.D.
The Cancer Center - IRCCS
Humanitas Research Hospital & Humanitas University-Politecnico di Milano

Genomic of myelodysplastic syndrome
View Presentation
(BCM login required)

March 7, 2022 Christopher Hourigan, M.D., D.Phil
National Institutes of Health

Advances in AML Measurable residual disease

This presentation will not be recorded.

March 21, 2022 Alexander Hollein 
Rotkreuzklinikum Münche, Munich Leukemia Laboratory, Munich Germany
CHIP vs CHOP initiating mutations in myeloid malignant disorders
View Presentation
(BCM login required)
April 4, 2022 Raheleh Rahbari, Cancer Research UK Career Development Fellow
Sanger Wellcome Institute, London, UK

Mutational landscape of somatic and germline mutations
View Presentation
(BCM login required)

April 18, 2022 Ana Domestegui, Postdoctoral Fellow 
Institute of Biomedical Research, Barcelona, Spain
Ribosomal activation and Myc-driven lymphoma lethality
May 2, 2022 Narish Kikkeri 
Fred Hutchinson Research Cancer Center 

Revisiting recognition and enumeration of blasts  in diagnosis and classification of myeloid neoplasm
View Presentation
(BCM login required)

May 16, 2022 Jean-Emmanuel Sarry
Centre de Recherches en Cancérologie de Toulouse
Mitochondrial inhibitors to overcome venetoclax and cytarabine resistance in AML 
June 6, 2022 Naseema Gangat
Mayo Clinic Rochester 
Primary refractory acute myeloid leukemia
View Presentation
(BCM login required)
July 11, 2022 Jorge Castillo, M.D.
Bing Center for Waldenstrom’s Macroglobulinemia
Division of Hematological Malignancies, Dana-Farber CanceInstitute
Harvard Medical School
 

Management of Waldenstrom’s Macroglobulinemia in the Era of Targeted Therapies
View Presentation
(BCM login required)

July 25, 2022

Daniel Starczynowski, Ph.D.
Cincinnati Children’s Hospital

TRAF6 as a novel tumor suppressor in myeloid malignancies
View Presentation
(BCM login required)

Aug. 8, 2022 Ann-Kathrin Eisfeld, M.D.
The Ohio State University
Racial disparity and differential outcome in AML
View Presentation
(BCM login required)
Sept. 12, 2022 Mikkael Sekeres, M.D., M.S., Chief of Hematology
University of Miami Hospital and Clinical
 
High-Risk Myelodysplastic Syndrome
View Presentation
(BCM login required)
Sept. 26, 2022 Dr. Karen H Miga, Ph.D., University of California Santa Cruz Discovering New Biology and Function in Complete, Telomere-to Telomere
(T2T) Genomes

Oct. 10, 2022

Phillip Awadalla, Ph.D.
Director, Computational Biology, Executive Scientific Director

The Evolutionary Dynamics of Clonal Hematopoiesis, Cancer Risk, and Healthy Blood Aging
View Presentation
(BCM login required)
Nov. 7, 2022 Cyrus Khandanpour, M.D.
Deputy Director and Professor, University
of Lübeck and University Hospital of Schleswig-Holstein

New Therapeutic Approaches for Leukemia
View Presentation
(BCM login required)

Dec. 14, 2022 Hitoshi Takizawa, Ph.D.
Vice-Director and Professor
International Research Center for Medical Sciences, Kumamoto University
Microbial signals in hematopoietic regulation
View Presentation
(BCM login required)